Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company will present data from the ongoing Phase IIa clinical trial with vafidemstat in Alzheimer’s disease (AD) named ETHERAL (Epigenetic THERapy in ALzheimer’s Disease) at the 2019 Alzheimer’s Association International Conference (AAIC-2019) to be held in Los Angeles (USA) on July 14-18.
Dr. Roger Bullock, Oryzon’s Medical Director, and Dr. Michael Ropacki, Oryzon’s Vice-President of Clinical Development, will attend the Conference. Dr. Bullock will present a written communication in the form of a Poster entitled “P#31419. Safety Evaluation of Vafidemstat on Mild to Moderate Alzheimer’s Subjects” at the session “Therapeutics: Clinical” to be held on Monday, July 15, 2019, 9:30 AM – 4:15 PM, at the Los Angeles Convention Center, South Hall GH. Safety data from the first 90 patients will be presented and the evolution of some relevant (blinded) functional parameters on the 33 first patients that have finished the first 6 months of treatment will be also discussed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.